Resource Summary Report

Generated by dkNET on Sep 3, 2026

OCI-Ly10

RRID:CVCL_8795
Type: Cell Line

Proper Citation

RRID:CVCL_8795

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_8795

Proper Citation: RRID:CVCL_8795

Description: Cell line OCI-Ly10 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse large B-cell lymphoma activated B-cell type

Defining Citation: PMID:3567358, PMID:8574164, PMID:10676951, PMID:15122589, PMID:20054396, PMID:20628145, PMID:20889926, PMID:21179087, PMID:23257783, PMID:23292937, PMID:25485619, PMID:25877200, PMID:26589293, PMID:26787899, PMID:28196595, PMID:29416618, PMID:29666304, PMID:30894373, PMID:31068700

Comments: Population: Caucasian., From: Ontario Cancer Institute (OCI); Toronto; Canada., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OCI-Ly10

Synonyms: OCI-LY10, OCI-LY-10, OCI-Ly 10, OCILY-10, OCI Ly10, OCILY10, OCILy10, Ly10, LY10

Cross References: EFO:EFO_0006708, ArrayExpress:E-MTAB-2706, BioSample:SAMN03470849, BioSample:SAMN10988192, cancercelllines:CVCL_8795, Cell_Model_Passport:SIDM01883, ChEMBL-Cells:CHEMBL4482983, ChEMBL-Targets:CHEMBL4483285, Cosmic:1134604, Cosmic:1329095, Cosmic:1486585, Cosmic:1487547, Cosmic:1517650, Cosmic:1541905, Cosmic:1550338, Cosmic:1945184,

Cosmic:2139542, Cosmic:2276333, Cosmic:2437310, DepMap:ACH-001146, EGA:EGAS00001000610, GEO:GSM1956, GEO:GSM2015, GEO:GSM2071, GEO:GSM552455, GEO:GSM1035340, GEO:GSM1059800, GEO:GSM1374784, GEO:GSM1890029, GEO:GSM1890030, GEO:GSM1890031, GEO:GSM1890032, Lonza:944, PharmacoDB:OCILY10_1188_2019, Progenetix:CVCL_8795, PubChem_Cell_line:CVCL_8795, Wikidata:Q54931760

ID: CVCL_8795

Record Creation Time: 20220427T221355+0000

Record Last Update: 20260829T235504+0000

Ratings and Alerts

No rating or validation information has been found for OCI-Ly10.

No alerts have been found for OCI-Ly10.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Zhang R, et al. (2025) Xenopus IgX informs engineering strategies of IgM and IgG hexamers. Science advances, 11(45), eaea3737.

Pieper NM, et al. (2024) Inhibition of bromodomain and extra-terminal proteins targets constitutively active NF?B and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell communication and signaling : CCS, 22(1), 415.

Phelan JD, et al. (2024) Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. Cancer cell, 42(2), 238.

Varier KM, et al. (2024) B4 suppresses lymphoma progression by inhibiting fibroblast growth factor binding protein 1 through intrinsic apoptosis. Frontiers in pharmacology, 15, 1408389.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Calbert ML, et al. (2024) 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Molecular cancer therapeutics, 23(5), 683.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. Blood cancer discovery, 5(6), 417.

Ji C, et al. (2023) Plasmodium falciparum has evolved multiple mechanisms to hijack human immunoglobulin M. Nature communications, 14(1), 2650.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. Cancer discovery, 13(8), 1862.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer discovery, 13(1), 216.

Delage L, et al. (2023) BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1. Blood, 141(10), 1209.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Kim DY, et al. (2022) Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma. Cancer research and treatment, 54(1), 301.

Varier KM, et al. (2022) Stilbene B10 induces apoptosis and tumor suppression in lymphoid Raji cells by BTK-mediated regulation of the KRAS/HDAC1/EP300/PEBP1 axis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 156, 113887.

Portelinha A, et al. (2021) ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell reports. Medicine, 2(7), 100350.

Carr M, et al. (2020) IKK? and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKK?/TBK1 inhibitor to repress NF-?B and IL-10 signalling. Journal of cellular and molecular medicine, 24(19), 11573.

Dietz A, et al. (2020) Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis. International journal of cancer, 147(5), 1485.

Qiu Z, et al. (2020) MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell chemical biology, 27(5), 538.

Lionakis MS, et al. (2017) Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer cell, 31(6), 833.